Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsJohn L Vaughn, MD, MS
Assistant Clinical ProfessorDownloadHi-Res Photo
About
Copy Link
Biography
John Vaughn is an Assistant Clinical Professor of Medicine. He received his medical degree from Ohio State University. He completed a residency in Internal Medicine at Ohio State University. He completed a fellowship in Hematology & Medical Oncology at NewYork-Presbyterian Weill Cornell Medical Center. He completed a fellowship in Bone Marrow Transplantation at Memorial Sloan Kettering Cancer Center. As a hospitalist, Dr. Vaughn's clinical practice focuses on the management of hospitalized patients with hematologic malignancies, including those receiving bone marrow transplants and cellular therapies. His research focus includes health services and outcomes research. He has a particular interest in the epidemiology of lymphoid malignancies. He participates in the education of medical students through the Yale Interprofessional Longitudinal Clinical Experience.
Last Updated on July 12, 2023.
Appointments
Internal Medicine
Assistant Clinical ProfessorPrimary
Other Departments & Organizations
Education & Training
- Fellow
- Memorial Sloan Kettering Cancer Center (2022)
- Fellow
- NewYork-Presbyterian Weill Cornell Medical Center (2021)
- MS
- Cornell University, Clinical Epidemiology & Health Services Research (2021)
- Resident
- The Ohio State University (2017)
- MD
- The Ohio State University (2014)
Research
Copy Link
Overview
Medical Research Interests
Epidemiology; Health Services Research; Lymphoma
ORCID
0000-0001-8122-3852
Research at a Glance
Yale Co-Authors
Frequent collaborators of John L Vaughn's published research.
Publications Timeline
A big-picture view of John L Vaughn's research output by year.
Research Interests
Research topics John L Vaughn is interested in exploring.
Jensa Morris, MD
Bonnie E Gould Rothberg, MD, PhD, MPH, MMM, FACP
Deborah Doroshow, MD, PhD
Elizabeth Horn Prsic, MD
Shalin Kothari, MD
Tarsheen Sethi, MD, MSc
23Publications
63Citations
Lymphoma
Publications
2025
Site-specific prognosis and temporal trends in extranodal marginal zone lymphoma patients in the United States
Munir M, Vaughn J, Rimmalapudi S, Epperla N. Site-specific prognosis and temporal trends in extranodal marginal zone lymphoma patients in the United States. Blood Cancer Journal 2025, 15: 201. PMID: 41271637, PMCID: PMC12638744, DOI: 10.1038/s41408-025-01424-4.Peer-Reviewed Original ResearchEvaluation of incidence and outcomes of transformed nodular lymphocyte predominant Hodgkin lymphoma in the United States: A population based cohort study
Vaughn J, Munir M, Epperla N. Evaluation of incidence and outcomes of transformed nodular lymphocyte predominant Hodgkin lymphoma in the United States: A population based cohort study. Blood 2025, 146: 6337. DOI: 10.1182/blood-2025-6337.Peer-Reviewed Original ResearchConceptsNodular lymphocyte predominant Hodgkin lymphomaDiffuse large B-cell lymphomaDe novo diffuse large B-cell lymphomaLymphoma-specific survivalLymphocyte predominant Hodgkin lymphomaHistological transformationB-cell lymphomaOutcomes of patientsCumulative incidenceHodgkin lymphomaOverall survivalRelative survivalSurvival outcomesNo significant differenceDiagnosis of nodular lymphocyte predominant Hodgkin lymphomaDiagnosis of diffuse large B-cell lymphomaRare indolent B-cell lymphomaCohort studyHazard ratioIncidence of histological transformationIndolent B-cell lymphomaLarge B-cell lymphomaSurvival rateCumulative incidence of deathCumulative incidence of HTPOSTER: ABCL-942 Pola-R-Mini-CHP for Untreated Diffuse Large B-Cell Lymphoma in Patients Who Are Elderly With Comorbid Conditions
Shah K, Forrest P, Sreedhar A, Sun A, Tegla C, Vaughn J, Braunstein M, Renteria A, Gerber J, Leonard J, Diefenbach C, Lahoud O. POSTER: ABCL-942 Pola-R-Mini-CHP for Untreated Diffuse Large B-Cell Lymphoma in Patients Who Are Elderly With Comorbid Conditions. Clinical Lymphoma Myeloma & Leukemia 2025, 25: s264. DOI: 10.1016/s2152-2650(25)01050-x.Peer-Reviewed Original ResearchABCL-942: Pola-R-Mini-CHP for Untreated Diffuse Large B-Cell Lymphoma in Patients Who Are Elderly With Comorbid Conditions
Shah K, Forrest P, Sreedhar A, Sun A, Tegla C, Vaughn J, Braunstein M, Renteria A, Gerber J, Leonard J, Diefenbach C, Lahoud O. ABCL-942: Pola-R-Mini-CHP for Untreated Diffuse Large B-Cell Lymphoma in Patients Who Are Elderly With Comorbid Conditions. Clinical Lymphoma Myeloma & Leukemia 2025, 25: s771-s772. DOI: 10.1016/s2152-2650(25)02325-0.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaRelative dose intensityPola-R-CHPProgression-free survivalComplete response rateLarge B-cell lymphomaOverall response rateDesign Retrospective chart reviewR-mini-CHOPB-cell lymphomaOverall survivalCharlson Comorbidity IndexAdverse eventsPolatuzumab vedotinSignificant comorbiditiesCumulative incidenceUntreated diffuse large B-cell lymphomaCumulative incidence of grade 3Follow-upEstimate PFSMedian progression-free survivalMedian relative dose intensityResults Median follow-upIncidence of grade 3Median Charlson comorbidity indexCD19 Directed CAR T Therapy for Transformed Follicular Lymphoma: A CIBMTR Analysis
Thiruvengadam S, Ahn K, Patel J, Lian Q, Hertzberg M, Epperla N, Metheny L, Hong S, Jain T, Aljurf M, Beitinjaneh A, Vaughn J, Gopal A, Iqbal M, Wirk B, Manjappa S, Oliver C, Mohty R, Shadman M, Turtle C, Hamadani M, Herrera A. CD19 Directed CAR T Therapy for Transformed Follicular Lymphoma: A CIBMTR Analysis. American Journal Of Hematology 2025, 100: 1803-1812. PMID: 40762207, PMCID: PMC12582634, DOI: 10.1002/ajh.70027.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsTransformed follicular lymphomaNon-relapse mortalityProgression-free survivalCAR-T infusionCAR-T therapyCytokine release syndromeCAR-TOverall survivalFollicular lymphomaT therapyCumulative incidenceCD19-directed chimeric antigen receptor T cellsCenter for International Blood and Marrow Transplant Research registryT infusionAssociated with inferior progression-free survivalChimeric antigen receptor T cellsCD19 CAR-T therapyCumulative incidence of relapseInferior progression-free survivalRisk of non-relapse mortalityAssociated with chemotherapy resistanceMedian prior linesCD19-CAR-TIncidence of relapseAxicabtagene ciloleucelComparison of artificial intelligence to expert physician assessments of real-world oncology cases.
Main O, Struck M, Vaughn J, Hsu J, Saint Fleur-Lominy S, Abu Zaid M, Braunstein M. Comparison of artificial intelligence to expert physician assessments of real-world oncology cases. Journal Of Clinical Oncology 2025, 43: 1564-1564. DOI: 10.1200/jco.2025.43.16_suppl.1564.Peer-Reviewed Original ResearchConceptsArtificial intelligenceAI toolsUser-generated queriesReal-world caseAI responseExpert physician assessmentIntelligenceMyeloid disordersLymphoma casesOncology casesHematological conditionsDecision makingExpertsDe-identified casesPhysician assessmentExpert oncologistsAI groupClinical decision makingPractical valueQueryManagement paradigmOncology fieldDisease subtypesClinical practiceMedical journalsAssociation of CAR-T approval on outcomes in patients with diffuse large B-cell lymphoma at the population level in the United States
Vaughn J, Ramdhanny A, Munir M, Rimmalapudi S, Epperla N. Association of CAR-T approval on outcomes in patients with diffuse large B-cell lymphoma at the population level in the United States. Biomarker Research 2025, 13: 64. PMID: 40275414, PMCID: PMC12023351, DOI: 10.1186/s40364-025-00780-4.Peer-Reviewed Original ResearchCitationsConceptsLymphoma-specific survivalOverall survivalCAR-TRelative survivalChimeric antigen receptor T cellsDiffuse large B-cell lymphomaLarge B-cell lymphomaCumulative incidence of deathB-cell lymphomaPopulation-based cohort studyReceipt of chemotherapyIncidence of deathPeriod of diagnosisRefractory DLBCLB symptomsMultivariate survival modelsMedian ageT cellsImproved survivalCumulative incidenceSEER-17Disease courseCohort studyDisease stageFDA approvalInpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis
Riaz F, Vaughn J, Zhu H, Dickerson J, Sayegh H, Brongiel S, Baldwin E, Kier M, Zaemes J, Hearn C, Abdelghany O, Cohen R, Parikh R, Reuss J, Prsic E, Doroshow D. Inpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis. JCO Oncology Practice 2025, 21: 1165-1173. PMID: 39937997, DOI: 10.1200/op-24-00788.Peer-Reviewed Original ResearchCitationsAltmetricConceptsImmune checkpoint inhibitorsOverall survivalICI administrationSolid malignanciesPatients treated with immune checkpoint inhibitorsAdministration of immune checkpoint inhibitorsMultivariate Cox proportional hazards model analysisResponse to ICI therapyCox proportional hazards model analysisProportional hazards model analysisAdvanced solid malignanciesKaplan-Meier methodOutcomes of patientsInstitutional electronic medical recordsHazards model analysisCox proportional hazards modelsProportional hazards modelCheckpoint inhibitorsICI therapyMedian OSICI initiationICI useRetrospective studyClinical outcomesClinicodemographic variables
2024
A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study
Vaughn J, Ramdhanny A, Munir M, Rimmalapudi S, Epperla N. A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study. Blood Cancer Journal 2024, 14: 212. PMID: 39609401, PMCID: PMC11604794, DOI: 10.1038/s41408-024-01194-5.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsIndolent non-Hodgkin lymphomaLymphoma-specific survivalDe novo DLBCLOverall survivalIndolent lymphomaT-FLHistological transformationRelative survivalDe novo diffuse large B-cell lymphomaIndolent non-Hodgkin's lymphoma subtypesDiffuse large B-cell lymphomaReceipt of prior chemotherapyAssociated with inferior survivalLarge B-cell lymphomaMedian follow-up timeStudy of adult patientsLymphoplasmacytic lymphoma/Waldenstrom macroglobulinemiaTransformed indolent lymphomaMarginal zone lymphomaNon-Hodgkin's lymphomaB-cell lymphomaTransformed follicular lymphomaIncidence of HTPopulation-based cohort studyPopulation-based studyImpact of Chimeric Antigen Receptor T-Cell Therapy on Survival in Patients with Diffuse Large B-Cell Lymphoma at the Population Level in the United States
Ramdhanny A, Vaughn J, Epperla N. Impact of Chimeric Antigen Receptor T-Cell Therapy on Survival in Patients with Diffuse Large B-Cell Lymphoma at the Population Level in the United States. Blood 2024, 144: 3745. DOI: 10.1182/blood-2024-211747.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaCAR-T cell therapyT-cell therapyChimeric antigen receptorChimeric antigen receptor T-cell therapyPresence of B symptomsLarge B-cell lymphomaB-cell lymphomaOverall survivalFood and Drug AdministrationRelative survivalB symptomsApproval of CAR-T cell therapyAdvent of chimeric antigen receptorCentral nervous system lymphomaMultivariable flexible parametric survival modelNervous system lymphomaMedian Follow-UpUS Food and Drug AdministrationPopulation-based cohort studySurveillance, EpidemiologyPeriod of diagnosisUS populationPersons per yearP-value <